The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

• Status: Recruiting
• Trial end date: 2024-12-31

Summary

To compare The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy.

• Phase: Phase 3

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Calcium; Calcium, Dietary; Leucovorin; Levoleucovorin; Oxaliplatin